Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 715

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Open access
Armstrong, Deborah K., Alvarez, Ronald D., Bakkum-Gamez, Jamie N., Barroilhet, Lisa, Behbakht, Kian, Berchuck, Andrew, Chen, Lee-may, Cristea, Mihaela, DeRosa, Maria, Eisenhauer, Eric L., Gershenson, David M., Gray, Heidi J., Grisham, Rachel, Hakam, Ardeshir, Jain, Angela, Karam, Amer, Konecny, Gottfried E., Leath, Charles A., Liu, Joyce, Mahdi, Haider, Martin, Lainie, Matei, Daniela, McHale, Michael, McLean, Karen, Miller, David S., O’Malley, David M., Percac-Lima, Sanja, Ratner, Elena, Remmenga, Steven W., Vargas, Roberto, Werner, Theresa L., Zsiros, Emese, Burns, Jennifer L., Engh, Anita M.·2021·Journal of the National Comprehensive Cancer Network

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes─high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2021.0007

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 134 references

Cited by

See all 715

Metadata

Authors
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Cristea, M., DeRosa, M., Eisenhauer, E. L., Gershenson, D. M., Gray, H. J., Grisham, R., Hakam, A., Jain, A., Karam, A., Konecny, G. E., Leath, C. A., Liu, J., Mahdi, H., Martin, L., Matei, D., McHale, M., McLean, K., Miller, D. S., O’Malley, D. M., Percac-Lima, S., Ratner, E., Remmenga, S. W., Vargas, R., Werner, T. L., Zsiros, E., Burns, J. L., & Engh, A. M.
Venue
Journal of the National Comprehensive Cancer Network
Published
2021-02
Volume
19
Issue
2
Pages
191-226
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
OpenAlex
W3201437718
Cited by
715
References
134
FWCI
91.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. https://app.cochat.ai/papers/10.6004/jnccn.2021.0007
The paper
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Cristea, M., DeRosa, M., Eisenhauer, E. L., Gershenson, D. M., Gray, H. J., Grisham, R., Hakam, A., Jain, A., Karam, A., Konecny, G. E., Leath, C. A., Liu, J., . . . Engh, A. M. (2021). Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2021.0007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.